Viewing Study NCT00122356



Ignite Creation Date: 2024-05-05 @ 11:45 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00122356
Status: COMPLETED
Last Update Posted: 2013-03-13
First Post: 2005-07-20

Brief Title: Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Sponsor: Barwon Health
Organization: Barwon Health

Study Overview

Official Title: Maintaining Skeletal Health in Postmenopausal Women With Surgically Resected Stage I-IIIa Hormone-receptor Positive Breast Cancer Who Are Receiving Anastrozole Through the Use of Alendronate as Determined by the Osteoporosis Australia Bone Maintenance Algorithm
Status: COMPLETED
Status Verified Date: 2013-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BATMAN
Brief Summary: The purpose of this study is to evaluate the use of an oral bisphosphonate alendronate in preventing bone loss in postmenopausal women with early breast cancer who are receiving anastrozole therapy and to determine how long alendronate treatment is needed
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None